Short Communication Cinromide's Metabolite in Monkey Model: Gastric Administration and Seizure Control

Abstract

In a previous study Cinromide (3 bromo-N-ethylcinnamamide [BEC]), an experimental anticonvulsant, was given a preliminary evaluation. Since that research was concerned primarily with EEG paroxysms, this study was conducted to address drug efficacy in terms of clinical seizures. Cinromide''s major metabolite (3-bromocinnamamide, BC) was the main focus. Alumina-gel rhesus monkeys (8) were given by gastric bolus every 6 h for 10 days (Phase I) either the solvent alone (Tween 80), Cinromide (BEC), or its synthetic metabolite (SBC). Subsequently (Phase II), 4 animals were given BEC or SBC by chronic gastric infusion for 20 days. In both phases Cinromide''s metabolite (either via BEC or especially SBC) was effective in half of the animals in reducing seizure frequency and/or duration at plasma levels above 5 mcg/ml. The drug''s efficacy was perhaps individually specific. Another species of Cinromide metabolism, 3-bromocinnamic acid, was also discussed.